The positive (factual) news is that the FDA has informed A2M that their application is actively being reviewed now (as opposed to just gathering dust in the queue for the past two months).
The AFR then proceeded to blow this out of proportion, most likely just to get more clicks.
I think an approval is still more likely than not, but I already did before yesterday.
A2M Price at posting:
$4.90 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)